| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Champions Oncology, Inc.$5.75
-0.03 (-0.52%)
F 16Pipeline Score Tools & Services · Clinical
Market Cap
83.46 M
EPS
-0.17
P/E Ratio
-
Value Trade
74.98 K
SEC Financials
Q1 2026Dilution Risk
Revenue
16.56 M
R&D Expenses
2.27 M
Total Assets
28.45 M
Total Liabilities
24.07 M
Equity
4.28 M
D/E Ratio
12,345
-5.35 %
Week
1.52 %
1 Month
3.09 %
3 Month
-9.35 %
6 Month
-39.17 %
5 Year
15.09 %
All Time
Cash Data
Cash Position
7.13 M
Monthly Burn
92.00 K
Runway
73.5 mo
Burn Trend
SEC Filing
Mar 12, 2026
Overview
Volume
3.79 K
52 Week Range
5.50 - 9.63
% held by Insiders
56.28 %
% held by Institutions
17.86 %
Enterprise Value
81.43 M
Total Shares
13.88 M
Short %
1.27 %
Float Shares
5.05 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Champions Oncology, Inc.
141Total events
0Upcoming
13Tier-1 (high impact)
2009 – 2026Coverage
Event history 2
TBD
◆Poster PresentationPresentation
Subscribe to view catalyst details
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F16
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 14%
Micro Cap (rank 785 of 912)
Percentile RankChampions Oncology, Inc. has significant pipeline risk (16/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CSBR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CSBR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CSBRChampions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
Champions Oncology will present new data at the AACR 2026 Annual Meeting, showcasing eight studies that focus on oncology drug development. The research covers various cancer types and emphasizes the importance of understanding therapeutic responses and resistance. The company aims to help biopharma partners make informed decisions earlier in the development process. CEO Rob Brainin highlights the significance of combining patient-derived models with molecular data.
Read more →CSBR▲ +6.3%on this news
Champions Oncology Reports Revenue of $16.6 Million
Champions Oncology reported a record study service revenue of $16.6 million for Q3 FY2026, marking a 32% increase year-over-year. Despite a slight decline in total revenue compared to the previous year, the company achieved its third consecutive quarter of positive adjusted EBITDA. CEO Robert Brainin expressed confidence in ongoing growth, particularly in their data business, while acknowledging fluctuations in quarterly results.
Read more →CSBRAbout Champions Oncology, Inc. Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R D solutions and innovative data platforms to biopharma organizations. Wi
Champions Oncology, Inc. (NASDAQ: CSBR) reported its financial results for the third quarter of fiscal 2026, highlighting record study service revenue of $16.6 million, a 32% increase year-over-year. Despite this growth, total revenue saw a slight decline due to the absence of a previous data license transaction. The company's adjusted EBITDA remained positive at $574,000, indicating operational improvements. However, net losses and increased operating costs pose challenges for the upcoming quarters.
Read more →CSBR▲ +16.1%on this news
not be considered in isolation or as a substitute for GAAP measures such as operating income (loss) and net income (loss). A reconciliation to the most directly comparable GAAP measure is provided in the accompanying tab
Champions Oncology, Inc. (Nasdaq CSBR) reported its financial results for the second quarter of fiscal 2026, highlighting an 11% increase in total revenue to $15 million compared to the previous year's quarter. Despite a net income of $237,000, which is lower than last year's equivalent, the company reported improved oncology services margins and maintained a positive adjusted EBITDA of $843,000. The management remains confident about sustainable revenue growth and is investing in its data platform to drive long-term value. The overall financial health shows both progress and challenges as expenses rise amidst ongoing investments.
Read more →CSBR▲ +21.5%on this news
Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug disc
Champions Oncology, Inc. reported its financial results for Q1 of FY 2026, with total revenue at $14 million. Despite a slight decline in service revenue, the company experienced growth in its data license revenue. Newly appointed CEO Rob Brainin expressed optimism about sustainable growth and operational improvements. However, the financial report also highlighted a loss from operations and increased operating costs, indicating challenges alongside positive developments in revenue and market positioning.
Read more →CSBRthis press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law. Champions Oncology, Inc. (Dollars in thousands) Reconciliation of GAAP Net I
Champions Oncology, Inc. reported a strong financial performance for the fiscal year 2025, with record annual revenue reaching $57 million, marking a 14% increase from the previous year. The company achieved net income of $4.6 million and adjusted EBITDA income of $7.1 million. However, the fourth quarter saw a decline in revenue by 12% and a loss from operations of $2 million. Despite these challenges, the company is optimistic about its growth prospects for fiscal 2026, driven by a solid pipeline and operational efficiencies.
Read more →CSBR▲ +10%on this news
on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the f
Champions Oncology, Inc. (Nasdaq: CSBR) reported compelling financial results for the third quarter of fiscal 2025, with total revenue increasing by 42% to $17.0 million and net income of $4.5 million. This quarter marks a transformative period for the company, notably due to its inaugural data licensing agreement valued at up to $8 million. Despite prevailing funding challenges in the biotech sector, Champions expressed confidence in maintaining strong performance driven by operational efficiencies and strategic cost alignments. Overall, the company has positioned itself for sustained long-term growth amidst a backdrop of improved financial metrics.
Read more →CSBR▲ +12.1%on this news
Non-GAAP Financial Information See the attached Reconciliation of GAAP net income (loss) to Non-GAAP net income (loss) for an explanation of the amounts excluded to arrive at Non-GAAP net income (loss) and related Non-GA
Champions Oncology, Inc. reported a 17% increase in total revenue, reaching $13.5 million for the second quarter of fiscal 2025. The company also achieved a positive adjusted EBITDA of $1.1 million and reiterated its optimistic outlook, projecting revenue growth of 10%-15% for the year. Despite these gains, research and development expenses saw a sharp decline, while costs related to oncology services increased slightly due to higher mouse costs. Overall, the results reflect operational efficiencies and a focus on enhancing revenue streams.
Read more →CSBRAbout Champions Oncology, Inc. Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R D solutions to biopharma organizations. With the largest and most annota
Champions Oncology, Inc. reported mixed financial results for the fiscal year ended April 30, 2024. While fourth quarter revenue rose by 7% to $14 million, the annual revenue saw a 7% decline. The company experienced an adjusted EBITDA loss of $3.9 million for the fiscal year, attributed to a challenging funding environment. However, cost-cutting measures began showing results in the fourth quarter, leading to an adjusted EBITDA income. The CEO expressed optimism about recovery signs in the market as the company prepares for fiscal 2025.
Read more →CSBRloss divided by the weighted average number of diluted shares outstanding. Champions' definition of Non-GAAP net loss and Non-GAAP diluted loss per share may differ from similarly named measures used by other companies a
Champions Oncology reported a third quarter revenue of $12.0 million, marking a 6% decline year-over-year. The gross margin also decreased to 35% as operational inefficiencies contributed to lower revenue. Despite these challenges, CEO Ronnie Morris highlighted confidence in future recovery and ongoing capital raising efforts for its subsidiary, Corellia, AI. The company's third-quarter loss from operations was $2.6 million, with strategic adjustments planned to improve performance moving forward.
Read more →CSBR▼ -6.5%on this news
See the attached Reconciliation of GAAP net loss to Non-GAAP net income (loss) for an explanation of the amounts excluded to arrive at Non-GAAP net income (loss) and related Non-GAAP income (loss) per share amounts for t
Champions Oncology, Inc. has reported its financial results for the second quarter of fiscal 2024, revealing a 19% decline in revenue to $11.6 million compared to the same period last year. The company revised its fiscal year revenue guidance to align with last year’s results amid a challenging economic environment impacting the biotech sector. Despite recent customer cancellations affecting revenue, management noted a recent resurgence in demand for its services and a healthy sales pipeline. Efforts are underway to raise capital for ongoing drug discovery initiatives and strategic developments under new leadership.
Read more →CSBRWebsite www.championsoncology.com Facebook https www.facebook.com championsoncology LinkedIn https www.linkedin.com company champions-oncology-inc- Twitter https twitter.com ChampionsOncol1 Instagram https www.instagram.
Champions Oncology, Inc. has appointed Brady Davis as its new President, aiming to advance strategic initiatives for accelerated growth. With over 25 years of international experience in the healthcare sector, Davis brings a strong background in medical instruments and data solutions. He will work alongside the executive team to enhance the company's market positioning and efficiency in oncology research. The appointment comes at a time of notable advancements in cancer research, aligning with Champions Oncology's commitment to innovative solutions.
Read more →CSBRFull details of the Company's financial results will be available by
Champions Oncology, Inc. reported its first quarter financial results for fiscal 2024, revealing a revenue of $12.6 million, which represents a decline of 9% from the previous year. Despite the revenue decrease attributed to customer cancellations, the company noted strong bookings and improving trends in customer spending. The CEO highlighted ongoing progress in their drug discovery initiatives while acknowledging the challenges faced due to economic downturns impacting the biotech sector. The total operating loss for the quarter was reported at $2.6 million, with operating costs rising to $15.1 million.
Read more →CSBR▼ -8%on this news
share amounts as non-GAAP net income (loss) divided by the weighted average number of diluted shares outstanding. Champions' definition of non-GAAP net income (loss) and non-GAAP diluted income (loss) per share may diffe
Champions Oncology (CSBR) announced its financial results for the fourth quarter and fiscal year ended April 30, 2023, reporting a fourth-quarter revenue of $13.1 million, which reflects a 2% increase year-over-year. The company achieved record annual revenue of $53.9 million, a 10% increase from the previous year, along with a significant 15% rise in year-over-year bookings. Despite these positive metrics, Champions reported a loss from operations of $2.5 million in the fourth quarter and noted the impact of study cancellations on profitability. The company emphasized its ongoing expansion efforts, including the launch of its new subsidiary, Corellia AI, aimed at enhancing therapeutic discovery.
Read more →CSBR▲ +5.3%on this news
About Champions Oncology, Inc. Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provi
Champions Oncology, Inc. (CSBR) has approved a $5 million stock repurchase program, reflecting confidence in its business prospects. The announcement was made by CEO Ronnie Morris, who aims to enhance shareholder value through strategic capital deployment. CFO David Miller noted that the current market valuation presents an attractive opportunity for the buyback. The repurchase will occur based on market conditions and is not guaranteed to reach the entire authorized amount.
Read more →CSBRperformance and trends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis. Certain unusual or non-recurring items that management does not beli
Champions Oncology, Inc. reported its third quarter financial results for fiscal 2023, revealing quarterly revenue of $12.8 million, a 3.2% decline year-over-year. Despite record bookings, the company faced challenges due to increased cancellations and rising operating expenses, leading to an adjusted EBITDA loss of $1.6 million. CEO Ronnie Morris emphasized the company's commitment to long-term investments in drug discovery, while CFO David Miller noted they are well-positioned for future revenue growth despite current setbacks.
Read more →CSBR▲ +5.2%on this news· ran to -27% by day 1
management does not believe affect the Company's basic operations do not meet the GAAP definition of unusual or non-recurring items. Non-GAAP net income and Non-GAAP earnings per share are not, and should not, be viewed
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $14.3 Million Hackensack, NJ - December 13, 2022 - Champions Oncology, Inc. (Nasdaq CSBR), a leading global technology-enabled biotech that is transformi
Read more →CSBRSee the attached Reconciliation of GAAP net income (loss) to Non-GAAP net income for an explanation of the amounts excluded to arrive at Non-GAAP net income and related Non-GAAP earnings per share amounts for the three m
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $13.7 Million Hackensack, NJ - September 8, 2022 - Champions Oncology, Inc. (Nasdaq CSBR), a leading global technology-enabled biotech that is transformi
Read more →CSBRChampions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R D services to
One University Plaza, Suite 307 Hackensack, NJ 07601 Champions Oncology Reports Quarterly Revenue of $12.9 Million Record Annual Revenue of $49.1 Million Hackensack, NJ - July 21, 2022 - Champions Oncology, Inc. (Nasdaq CSBR), a leading global technology-enabled biotech that i
Read more →CSBRtrends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis. Certain unusual or non-recurring items that management does not believe affect the C
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $13.2 Million Reported Adjusted EBITDA of $1.5 million Hackensack, NJ - March 15, 2022 - Champions Oncology, Inc. (Nasdaq CSBR), a leading global techno
Read more →CSBRa substitute for similar GAAP items. Champions defines Non-GAAP dilutive earnings per share amounts as Non-GAAP net earnings divided by the weighted average number of diluted shares outstanding. Champions' definition of
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $11.8 Million Reported income from operations of $263,000 Hackensack, NJ - December 13, 2021 - Champions Oncology, Inc. (Nasdaq CSBR), a leading global
Read more →CSBRChampions Oncology is a technology-driven research organization that provides end-to-end R D service solutions, an industry-leading data visualization and analyses software, Lumin Bioinformatics, and is transforming drug
One University Plaza, Suite 307 Hackensack, NJ 07601 Champions Oncology Reports Quarterly Revenue of $10.6 Million Record Annual Revenue of $41 Million Hackensack, NJ - July 22, 2021 - Champions Oncology, Inc. (Nasdaq CSBR), engaged in creating transformative technology soluti
Read more →CSBRNon-GAAP Financial Information See the attached Reconciliation of GAAP net income to Non-GAAP net income for an explanation of the amounts excluded to arrive at Non-GAAP net income and related Non-GAAP earnings per share
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $10.8 Million Hackensack, NJ - March 11, 2021 - Champions Oncology, Inc. (Nasdaq CSBR), a leading global oncology technology solutions provider engaged i
Read more →CSBRSee the attached Reconciliation of GAAP net income (loss) to Non-GAAP net income (loss) for an explanation of the amounts excluded to arrive at Non-GAAP net income (loss) and related Non-GAAP earnings (loss) per share am
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $10.1 Million Launches Lumin Bioinformatics SaaS platform Hackensack, NJ - December 14, 2020 - Champions Oncology, Inc. (Nasdaq CSBR), a leading global
Read more →CSBRearnings (loss) per share amounts for the three months ended
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $9.5 Million Hackensack, NJ - September 14, 2020 - Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development t
Read more →CSBRengraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjuncti
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Quarterly Revenue of $8.8 Million Record Annual Revenue of $32.1 Million Hackensack, NJ - July 27, 2020 - Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range o
Read more →CSBRAbout Champions Oncology, Inc. About Champions Oncology Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The C
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Quarterly Revenue of $9.0 Million Hackensack, NJ - March 12, 2020 - Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development techn
Read more →CSBROncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on th
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019 Record Annual Revenue of $27 Million Hackensack, NJ - July 15, 2019 - Champions Oncology, Inc.
Read more →CSBRGAAP net income (loss) and Non-GAAP earnings (loss) per share are not, and should not be viewed as a substitute for similar GAAP items. Champions' defines Non-GAAP dilutive earnings (loss) per share amounts as Non-GAAP n
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Quarterly Revenue of $6.4 Million Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 Hackensack, NJ - March 18, 2019 - Champions Oncology, Inc. (Nasda
Read more →CSBRAbout Champions Oncology, Inc. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's TumorGraft techn
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Quarterly Revenue of $6.7 Million Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 Hackensack, NJ - December 17, 2018 - Champions Oncology, I
Read more →CSBRplatform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner th
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Quarterly Revenue of $6.2 Million Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 Hackensack, NJ - September 13, 2018 - Champions Oncology,
Read more →CSBRcompanies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and o
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018 Expects Revenue Growth of at Least 20% for Fiscal Year 2019 Hackensack, NJ - July 26, 2018 - Champions On
Read more →CSBRSee the attached Reconciliation of GAAP net loss to non-GAAP net loss for an explanation of the amounts excluded to arrive at non-GAAP net loss and related non-GAAP net loss per share amounts for the three and nine month
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Quarterly Revenue of $5.1 Million Company Generates Positive Cash Flow from Operations; Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2018 Hackensack
Read more →CSBRSee the attached Reconciliation of GAAP net loss to non-GAAP net loss for an explanation of the amounts excluded to arrive at non-GAAP net loss and related non-GAAP net loss per share amounts for the three and six months
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Quarterly Revenue of $5.2 Million Quarterly operating profit driven by double-digit revenue growth Hackensack, NJ - December 7, 2017 - Champions Oncology, Inc. (Nasdaq: CSB
Read more →CSBRtreatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new d
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Quarterly Revenue of $5 Million 37.1% year-over-year revenue increase Hackensack, NJ - September 14, 2017 - Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the developm
Read more →CSBRThis press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words su
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports 38% Revenue Growth for Fiscal Year Ended April 30, 2017 Hackensack, NJ - July 27, 2017 - Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology
Read more →CSBRrecurring items. Non-GAAP net loss and non-GAAP loss per share are not, and should not be viewed as a substitute for similar GAAP items. Champions' defines non-GAAP dilutive loss per share amounts as non-GAAP net loss di
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports 50% Revenue Growth, Accelerated Progress on Path to Profitability and Future Role Changes of the Senior Leadership Hackensack, NJ - November 29, 2016 - Champions Oncology, Inc. (Na
Read more →CSBRon a GAAP basis. Certain unusual or non-recurring items that management does not believe affect the Company's basic operations do not meet the GAAP definition of unusual or non-recurring items. Non-GAAP net loss and non-
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Beats Revenue Guidance for Quarter; Reaffirms Full Year Guidance of 43 - 60% Revenue Growth Hackensack, NJ - September 9, 2016 - Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the dev
Read more →CSBRChampions Oncology, Inc. Susan Foreman sforeman@championsoncology.com Telephone: 410-369-0365 Champions Oncology, Inc. Announces Pricing of Public Offering of Common Stock 2,000,000 Shares Priced at $2.25 Per S
Champions Oncology, Inc. sforeman@championsoncology.com Telephone: 410-369-0365 Champions Oncology, Inc. Announces Pricing of Public Offering of Common Stock 2,000,000 Shares Priced at $2.25 Per Hackensack, N.J., June 9, 2016 - Champions Oncology, Inc. (NASDAQ: CSBR), or t
Read more →CSBRInvestor Presentation May 2016 2 Notice of Forward Looking Statements Thispresentationcontainscertain"forward-lookingstatements,"whichincludeinformationrelatingtofutureevents, future financial performance, strategies, ex
1 Investor Presentation May 2016 2 Notice of Forward Looking Statements Thispresentationcontainscertain"forward-lookingstatements,"whichincludeinformationrelatingtofutureevents, future financial performance, strategies, expectations, competitive environment, regulation, and avai
Read more →CSBRNEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 For Immediate Release Champions Oncology Announces Addition to Board of Directors HACKENSACK, N.J.
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Announces Addition to HACKENSACK, N.J., April 12, 2016 -- Champions Oncology, Inc. (NASDAQ:CSBR) is pleased to announce the appointment of Dr. Philip Breitfeld to its Board of Directors.
Read more →CSBROne University Plaza, Suite
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for the Third Quarter Ended January 31, 2016 Hackensack, NJ - March 15, 2016 - Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutio
Read more →CSBRInvestor Presentation March 2016 2 Notice of Forward Looking Statements This presentation contains certain "forward - looking statements," which include information relating to future events, future financial performance
1 Investor Presentation March 2016 2 Notice of Forward Looking Statements This presentation contains certain "forward - looking statements," which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regu
Read more →CSBRChampions Oncology Reports
NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for the Second Quarter Ended October 31, 2015 December 14, 2015 - Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and se
Read more →CSBROne University Plaza Suite 307 Hackensack, NJ 07601 Phone: 201-808-8400 www.championsoncology.com Champions Oncology Announces Uplisting to NASDAQ Hackensack, NJ
Champions Oncology Announces Uplisting Hackensack, NJ - August 21, 2015 - Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced that it has commenced trading
Read more →CSBRChampions Oncology Announces Reverse Stock Split in Preparation for Uplisting to NASDAQ Hackensack, NJ
Champions Oncology Announces Reverse Stock Split in Preparation for Uplisting to NASDAQ Hackensack, NJ - August 12, 2015 - Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of
Read more →CSBRNEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for Quarter and Full Year Ended
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 July 28, 2015 - Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and servi
Read more →CSBRNEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for the Third Quarter Ended
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for the Third Quarter Ended January 31, 2015 March 17, 2015 - Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and servic
Read more →CSBRChampions Oncology Announces $14 Million Capital Raise Hackensack, NJ -March 12 , 2015 - Champions O ncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to person
Champions Oncology Announces $14 Million Capital Hackensack, NJ -March 12, 2015 - Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced
Read more →CSBRChampions Oncology Closes Convertible Debt Financing Hackensack, NJ
Closes Convertible Debt Financing NJ - December 5, 2014 - Champions Oncology, Inc., a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the closing of a $2 million converti
Read more →CSBRNEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for the First Quarter Ended
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for the First Quarter Ended July 31, 2014 September 11, 2014 - Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and serv
Read more →CSBRNEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 For Immediate Release Champions Oncology Reports Results for the Quarter Ended
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for the Quarter Ended July 31, 2013 September 13, 2013 - Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services t
Read more →CSBRNEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 For Immediate Release Champions Oncology Reports Results for the Quarter and Full Year Ended
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for the Quarter and Full Year Ended April 30, 2013 June 10, 2013 - Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and s
Read more →CSBRNEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 For Immediate Release Champions Oncology Reports Record Results for the Quarter Ended
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Results for the Quarter Ended January 31, 2013 March 14, 2013 - Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and servi
Read more →CSBRNEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 For Immediate Release Champions Oncology Reports Changes to Board of Directors Hackensack, NJ
NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Oncology Reports Changes to Board of Directors NJ - March 5, 2013 Champions Oncology, Inc. (OTC: CSBR) is pleased to announce the appointments of Dan Mendelson and Arthur G. ("Bart") Epker, III to the
Read more →CSBRNEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 For Immediate Release Champions Oncology Raises $9.3 Million in a Private Placement Hackensack, NJ
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Raises $9.3 Million in a Private Placement NJ - January 29, 2013 - Champions Oncology, Inc. (OTC: CSBR) ("the Company") announced today the company raised $9.3 million at a price of $0.
Read more →CSBRA proprietary in vivo testing and information platform for personalizing cancer care January 2013 Notice of Forward Looking Statements This presentation contains certain "forward - looking statements," which include info
A proprietary in vivo testing and information platform for personalizing cancer care January 2013 Notice of Forward Looking Statements This presentation contains certain "forward - looking statements," which include information relating to future events, future financial perform
Read more →CSBRNEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 For Immediate Release
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 CHAMPIONS ONCOLOGY REPORTS RESIGNATION August 3, 2012 - Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the developme
Read more →CSBRChampions Oncology, Inc. NEWS 1 University Plaza, Suite 307, Hackensack, NJ USA. Tel. 410-369-0365 For Immediate Release Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Managemen
Champions Oncology, Inc. NEWS 1 University Plaza, Suite 307, Hackensack, NJ USA. Tel. 410-369-0365 Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation Company Hires Gary G. Gemignani as Execut
Read more →CSBRChampions Biotechnology, Inc. NEWS 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA. Tel. 410-369-0365 For Immediate Release Champions Oncology Clarifies Misstatements in News Article BALTIMORE
Champions Biotechnology, Inc. 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA. Champions Oncology Clarifies Misstatements in News Article BALTIMORE, July 18, 2011. Champions Oncology, Inc., formerly Champions Biotechnology, Inc. (OTC: CSBR) released the following
Read more →CSBRChampions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing Baltimore, MD
Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing Baltimore, MD April 5, 2011 - Champions Oncology, Inc. (OTC: CSBR) ("the Company", formerly known as Champions Biotechnology, Inc.) announced today it has completed the private placement o
Read more →CSBRChampions Biotechnology, Inc. NEWS 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA. Tel. 410-369-0365 For Immediate Release Champions Biotechnology CFO Resigns Baltimore, MD
Champions Biotechnology, 855 N. Wolfe Street, Suite 619, Baltimore, Maryland Champions Biotechnology CFO Baltimore, MD, January 14, 2011 - Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive translational platform aimed at accelerating the
Read more →CSBRChampions Biotechnology, Inc. NEWS 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA. Tel. 410-369-0365 For Immediate Release Champions Biotechnology Reports Fiscal 2011 Second Quarter Financial Results Balti
Champions Biotechnology, 855 N. Wolfe Street, Suite 619, Baltimore, Maryland Champions Biotechnology Reports Fiscal 2011 Second Quarter Financial Results Baltimore, MD, December 13, 2010 - Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the de
Read more →CSBRChampions Biotechnology, Inc. NEWS 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA. Tel. 410-369-0365 For Immediate Release Champions Biotechnology Awarded $1.46 million in Grants Baltimore, MD
Champions Biotechnology, Inc. 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA. Champions Biotechnology Awarded $1.46 million in Grants Baltimore, MD, November 2, 2010 Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development
Read more →CSBRChampions Biotechnology, Inc. NEWS 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA. Tel. 410-369-0365 For Immediate Release Champions Biotechnology Reports Additions to its Management Team Baltimore, MD
Champions Biotechnology, Inc. 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA. Champions Biotechnology Reports Additions to its Management Team Baltimore, MD, October 28, 2010 Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the dev
Read more →CSBRChampions Biotechnology, Inc. NEWS 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA. Tel. 410-369-0365 For Immediate Release Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results Baltim
Champions Biotechnology, Inc. 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results Baltimore, MD, September 10, 2010 Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engage
Read more →CSBRChampions Biotechnology, Inc. NEWS 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA. Tel. 410-369-0365 For Immediate Release Champions Biotechnology Reports Fiscal 2010 Full-Year Financial Results Baltimore,
Champions Biotechnology, Inc. 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 USA. Champions Biotechnology Reports Fiscal 2010 Full-Year Financial Results Baltimore, MD, July 28, 2010 Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the
Read more →CSBRNEWS Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results Baltimore, MD
Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results Baltimore, MD March 17, 2010 Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value
Read more →CSBRChampions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results Baltimore, MD
Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Baltimore, MD, December 15, 2009-Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value o
Read more →CSBRNEWS Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results Baltimore, MD
Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results Baltimore, MD September 14, 2009-Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance th
Read more →CSBRChampions Biotechnology, Inc. NEWS 1400 North 14 th Street, Arlington, Virginia 22209 USA. Tel. 410-630-1313 For Immediate Release Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results Arlington, VA
Champions Biotechnology, Inc. NEWS 1400 North 14 th Street, Arlington, Virginia 22209 USA. Tel. 410-630-1313 Arlington, VA, July 30, 2008 -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor
Read more →CSBRChampions Sports, Inc CHAMPIONS Biotechnology, Inc. 2200 Wilson Boulevard, Suite 102-316 Arlington, VA 22201, USA Tel: 703-526-0400 Fax: 703-832-8311 Champions Biotechnology, Inc. acquires rights to cancer
CHAMPIONS Biotechnology, Inc. Boulevard, Suite 102-316 Arlington, VA 22201, USA Champions Biotechnology, Inc. acquires rights to cancer drug Arlington, VA., February 14, 2007. Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a development stage biotechnology company
Read more →Competitive Position
How CSBR ranks across every disease it competes inCompetitive Position is a premium feature
See how CSBR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial